Drugs / bis-octanoyl (R)-1,3-butanediol
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT07097506 | Sep 2025 → Jul 2027 expected | metabolic dysfunction-associated steatotic liver disease, obesity disorder | Washington University School of Medicine | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | bis-octanoyl (R)-1,3-butanediol | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07097506 ↗ |
| Known as | C8 ketone di-ester | “including bis-octanoyl (R)-1,3-butanediol (C8 ketone di-ester), which is hydrolyzed in the intestine to generate the ketone precursors octanoic acid and (R)-1,3-butanediol” NCT07097506 ↗ |